Diffuse alveolar hemorrhage (DAH) is an uncommon complication in patients with systemic lupus erythematosus (SLE), and mortality remains high. In recent years, cases of DAH due to SLE treated with extracorporeal membrane oxygenation (ECMO) have rarely been reported. The authors present a case of a 43-year-old woman with SLE who had rapidly aggravating dyspnea and hemoptysis. She was diagnosed as having DAH with refractory respiratory failure and was successfully managed with veno-venous ECMO. We propose ECMO as a useful salvage therapy in patients with alveolar hemorrhage secondary to SLE who are failing conventional ventilatory support.
Editorial
going a diagnostic lymph node biopsy of the right axilla.
She had no other medical problems except for axillary lymphadenopathy. The lymph node biopsy led to a diagnosis of atypical lymphoid hyperplasia. Initial work-up revealed diffuse bilateral multifocal patch consolidations and a ground glass appearance in both lungs on chest X-ray imaging (Fig. 1A) and chest computed tomography (Fig. 1B) . After ECMO was performed, a small amount of bleeding was observed with endobronchial suction. Procalcitonin and C-reactive protein levels were elevated. Because infection was not excluded, the patient received empiric therapy with broad spectrum antibiotics, immunosuppressive drugs such as cyclophosphamide were avoided, and plasmapheresis was performed to reduce inflammation related to highly active SLE.
ECMO was continued for 8 days. She recovered and was successfully extubated after 13 days of mechanical ventilation. At the time of discharge, the patient could breathe normally on room air and had no neurological sequelae (Fig. 3) . The patient was discharged from the hospital on oral prednisolone (50 mg/day) and she received IV cyclophosphamide administered every two weeks at an outpatient clinic.
Fig. 2. Chest radiography after the initiation of extracorporeal membrane oxygenation (ECMO). Chest radiography immediately
after the initiation of ECMO shows more aggravated bilateral alveolar infiltrates than seen on prior imaging studies.
Fig. 3.
Chest radiography prior to discharge. Chest radiography was performed prior to discharge and shows improvement in both lungs.
Discussion
We report the first case of ECMO in the setting of DAH secondary to SLE disease flare-up in Korea. DAH caused by SLE is scarce and life-threatening complication and sudden-onset dyspnea is the most consistent symptom.
[7] The incidence of hemoptysis varies between 25 and 100%, and the appearance of new-onset pulmonary infiltrates in both lungs and drops in hemoglobin may indicate DAH when hemoptysis is absent. The use of ECMO may reduce further lung injury related to high airway pressure and oxygen toxicity while allowing more time for aggressive anti-inflammatory therapy.
[9] When inflammation regulation against SLE is started immediately, these interventions should be successful.
The treatment strategy for DAH caused by SLE in adults is combination therapy using high-dose glucocorticoids and cytotoxic drug such as IV cyclophosphamide [11] and plasmapheresis. [12] As in our case, simultaneous use of ECMO and plasmapheresis has a advantage for sharing vascular access and has been applied for fatal alveolar hemorrhage secondary to other connective tissue diseases. [13] Because of the rarity of this fatal condition of DAH caused by SLE, there are no standard treatment guidelines. In addition to, an agreement for the optimal target level of systemic anticoagulation for patients with severe alveolar hemorrhage should be determined. Multi-institutional trials and data collection are needed to establish whether ECMO as a rescue therapy confers better survival outcomes in patients with DAH caused by SLE; in addition, development of safe strategies for anticoagulation in these patients is warranted.
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